Shares of METIS TECHBIO-P (07666) climbed more than 8% following the release of its interim results, with the stock trading up 7.97% at HK$14.90 as of the time of writing, on a turnover of HK$16.82 million.

On August 25, the company unveiled its 2026 interim financial report. During the reporting period, revenue reached RMB 154 million, a year-on-year surge of 13,339%, exceeding the total revenue for the entire previous year by 47%. Concurrently, the company's financial structure continued to improve: R&D expenses for the period grew 48.1% year-on-year to RMB 172 million; adjusted net losses narrowed significantly by 56.4% to RMB 51.1 million; and cash reserves stood at RMB 3.025 billion, while the debt-to-asset ratio improved from 19.3% at the end of 2025 to 9%.

With the commercial outcomes of NanoForge entering a phase of concentrated release, the core innovative value of METIS TECHBIO is expected to continue receiving dual validation from both global industry players and capital markets. In the first half of 2026, the platform capabilities of NanoForge gained tangible recognition from international professional investment institutions and leading multinational pharmaceutical companies, as the company consistently landed commercial milestones, once again demonstrating its capacity to generate globally valuable innovative assets.

Notably, the recent clinical validation of the world's first mRNA-based therapeutic cancer vaccine has confirmed the feasibility and commercial potential of mRNA technology in cancer treatment. Against this backdrop, the NanoForge platform's capabilities in mRNA tumor vaccine development and its role as a "pick-and-shovel" provider in LNP delivery have gained recognition in the secondary market, propelling the company's share price to a single-day peak gain of over 35%.